Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Prostaglandin Receptor Inhibitor
1,2,3-Trilinoelaidoyl glycerol acts as a prostaglandin receptor inhibitor, influencing the biosynthesis of prostaglandins and modulating platelet function. This compound also demonstrates significant effects on the fatty acid composition within rat organs, depending on the dosage administered. It serves as a valuable tool for examining dietary impacts on lipid metabolism and associated physiological parameters in preclinical research involving rodent models. -
Thromboxane Synthase Inhibitor
Furegrelate is a selective thromboxane synthase inhibitor that acts primarily by blocking the synthesis of thromboxane A2 (TxA2) in human platelets, exhibiting an IC50 of 15 nM. Its potent inhibitory action makes Furegrelate a valuable candidate for research applications focused on antiplatelet therapies. This compound is under investigation for its potential to mitigate thrombotic events associated with cardiovascular diseases. -
Thromboxane Synthetase Inhibitor
UK 34787 is a selective thromboxane synthetase inhibitor that exhibits minimal activity against cyclooxygenase and prostacyclin synthetase. This compound is utilized in research to study thromboxane's role in cardiovascular function and various pathophysiological conditions. Its specificity makes it a valuable tool in investigating the therapeutic potential of thromboxane modulation in disease models. -
Thromboxane Synthase Inhibitor
Wy 27569 is a thromboxane synthase inhibitor that modulates prostaglandin balance by decreasing pro-thrombotic thromboxane A2 (TXA2) and increasing anti-thrombotic prostacyclin (PGI2). This compound is known for its vascular selectivity and ability to effectively lower blood pressure. Wy 27569 is utilized in research on cardiovascular diseases, including hypertension and angina, making it valuable for understanding thrombotic processes and vascular health. -
Thromboxane A2 Synthetase Inhibitor
Nafagrel hydrochloride is a potent thromboxane A2 synthetase inhibitor. This compound effectively prevents thrombus formation, demonstrated in a rat model of acute arterial thrombosis. It is valuable for research applications related to cardiovascular disease, thrombosis, and related therapeutic interventions. -
Thromboxane Synthetase Inhibitor
Dazoxiben is an effective thromboxane synthetase inhibitor that functions to reduce thromboxane production, thereby influencing platelet aggregation and vasoconstriction. This compound is particularly relevant in the investigation of vascular conditions, such as Raynaud's syndrome, where thromboxane overproduction may play a critical role. Its oral bioavailability makes it suitable for in vivo studies on thromboxane-related pathologies. -
PGHS-2 Inhibitor
15(S)-HpEPE is a lipoxygenase-derived hydrolysis product of polyunsaturated fatty acids (PUFAs), serving as a potential inhibitor of prostaglandin H synthase 2 (PGHS-2). This compound has been shown to downregulate PGHS-2 expression, making it a valuable tool for research focused on inflammatory pathways and associated diseases. Its biological activity is of interest in studies examining the modulation of prostaglandin synthesis and the regulation of inflammatory responses. -
PTGR2 Inhibitor
RJG-2036 is a potent covalent inhibitor of human prostaglandin reductase 2 (PTGR2) with an IC50 value of 100 nM. This compound effectively inhibits NADPH-dependent reduction, leading to a significant decrease in the secretion of proinflammatory cytokines such as TNF-α and various eicosanoids in LPS-stimulated THP-1 macrophages. RJG-2036 serves as a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases. -
TxA2 Synthase/Receptor Inhibitor
Picotamide monohydrate is a dual inhibitor of thromboxane A2 (TxA2) synthase and its receptor, exhibiting significant antiplatelet activity. This compound has been shown to reduce microalbuminuria and inhibit the progression of carotid plaques in diabetic models. Picotamide monohydrate serves as a valuable tool for investigating both acute and chronic cardiovascular diseases in research settings. -
Prostaglandin E2 Inhibitor
Seprilose is a potent inhibitor of prostaglandin E2 synthesis, acting primarily by targeting the relevant enzymatic pathways involved in its production. This compound demonstrates significant anti-inflammatory activity, making it valuable for research applications focused on inflammation and related disorders. Seprilose can be utilized in studies examining the role of prostaglandins in various physiological and pathological processes. -
Thromboxane Synthase Inhibitor
Imitrodast is a selective thromboxane synthase inhibitor, effectively blocking the conversion of arachidonic acid to thromboxane A2. This compound demonstrates significant activity in modulating bronchoconstriction and possesses potential applications in research related to respiratory disorders and cardiovascular diseases. Its mechanism may help elucidate the role of thromboxane in various pathological conditions. -
Platelet Aggregation Inhibitor
Octimibate is a non-prostaglandin platelet aggregation inhibitor, acting primarily to prevent platelet activation and aggregation. This compound is utilized in research focused on cardiovascular diseases, specifically in the contexts of atherosclerosis and thrombosis, to elucidate the underlying mechanisms and potential therapeutic strategies for these conditions. -
Thromboxane Synthase Inhibitor
Rolafagrel is a selective inhibitor of thromboxane synthase, a key enzyme involved in the synthesis of thromboxane A2, which plays a pivotal role in platelet aggregation and vascular contraction. This compound has significant implications in cardiovascular research, facilitating the study of thromboxane-mediated pathways and their contribution to various cardiovascular disorders. Its use may aid in the development of therapeutic strategies targeting thromboxane-related conditions. -
DP2 Receptor Inhibitor
CRTh2 antagonist 4 is a selective inhibitor of the DP2 receptor, displaying an IC50 value of 212 nM and a binding affinity with a Ki of 37 nM. This compound is useful in the investigation of TH2 lymphocyte-related pathways and has potential applications in understanding and treating severe allergic diseases. -
Thromboxane Synthase Inhibitor
Imitrodast sodium is a potent thromboxane synthase inhibitor. This compound plays a significant role in research related to bronchoconstriction and its associated pathways. Its ability to inhibit thromboxane production offers insights into the mechanisms of allergic reactions and pulmonary function, making it valuable for studies focused on respiratory health and related conditions. -
TXA2 Receptor Inhibitor
BM-531 is a dual-action thromboxane receptor (TXA2) inhibitor that also functions as a thromboxane synthase inhibitor. This compound demonstrates significant anti-aggregatory effects on human citrated platelet-rich plasma, effectively inhibiting arachidonic acid-induced aggregation with an ED100 of 0.125 μM and U-46619-induced aggregation with an ED50 of 0.482 μM. Additionally, BM-531 is shown to inhibit contraction in porcine uterine smooth muscle induced by high potassium levels, making it a valuable tool for research in thrombosis and uterine contractility studies. -
Cyclooxygenase Inhibitor
KC-764 is an orally active, reversible inhibitor of cyclooxygenase, preferentially targeting platelet cyclooxygenase. It effectively reduces platelet thromboxane A2 (TXA2) production and inhibits platelet aggregation, exhibiting IC50 values of 0.23 μM and 26 nM, respectively. This compound is valuable for research focused on antiplatelet therapy and the prevention of recurrence in ischemic stroke. -
TXA2 Inhibitor
(E/Z)-Ozagrel sodium is a selective thromboxane A2 (TXA2) synthase inhibitor, exhibiting an IC50 value of 11 nM. By inhibiting TXA2 production, it promotes vasodilation and exhibits anti-platelet aggregation and anti-inflammatory effects through increased prostacyclin (PGI2) levels. This reagent is valuable for research into ischemic stroke, asthma, and thromboembolic diseases. -
FP/TP Receptor Inhibitor
CAY10535 is an inhibitor of the FP and TP receptors, targeting key pathways involved in cardiovascular function. This compound demonstrates potential for elucidating the role of these receptors in cardiovascular disease pathology. It serves as a valuable tool for researchers investigating therapeutic interventions aimed at modulating prostanoid signaling in cardiovascular conditions. -
Platelet Aggregation Inhibitor
MED 27 is a potent inhibitor of thromboxane synthase and thromboxane A2 receptors. It effectively inhibits rat platelet aggregation at significantly lower doses compared to acetylsalicylic acid. This compound is valuable for research applications focused on cardiovascular disorders and the mechanisms of platelet function. -
Prostaglandin Receptor Inhibitor
Iso-Samixogrel is a potent prostaglandin receptor inhibitor, functioning as both a thromboxane A2 receptor blocker and a thromboxane synthetase inhibitor. This compound demonstrates significant antithrombotic activity by effectively preventing recurrent arterial thrombus formation and inhibiting collagen-induced platelet aggregation in ex vivo studies. Additionally, Iso-Samixogrel prolongs sublingual bleeding time, indicating its potential utility in the management of thrombotic disorders. -
TXA2 Inhibitor
Isbogrel is a selective inhibitor of thromboxane A2 (TXA2) synthase, demonstrating potent activity in reducing TXA2 generation in the bloodstream. With an ID50 value of 0.04 mg/kg, Isbogrel exhibits effective oral bioavailability. This compound is primarily utilized in research focused on cardiovascular diseases and thrombotic disorders, contributing to the understanding of TXA2's role in platelet aggregation and vascular functions. -
Thromboxane Synthase Inhibitor
LG 82-4-00 is a selective thromboxane synthase inhibitor with an IC50 of 1.1 μM. This compound effectively inhibits collagen-induced formation of TXB2 and subsequently reduces platelet aggregation in plasma. LG 82-4-00 serves as a valuable tool in research focused on thrombotic disorders, contributing to the understanding of thromboxane's role in vascular biology and pathology. -
Platelet Inhibitor
Prostaglandin D3 (PGD3) is a natural prostaglandin that functions as an inhibitor of platelet aggregation. Its primary biological activity involves modulation of autonomic neurotransmission. PGD3 is utilized in research to study cardiovascular diseases and platelet activity, making it a valuable reagent for investigations into thrombosis and related conditions. -
Prostaglandin D Synthase Inhibitor
Pizuglanstat hydrate is a potent inhibitor of prostaglandin D synthase, exhibiting an IC50 of 76 nM for human hematopoietic prostaglandin D synthase. This compound effectively inhibits the synthesis of prostaglandin D2, making it relevant in research into inflammatory conditions. Pizuglanstat hydrate has demonstrated efficacy in improving experimental allergic rhinitis and offers potential applications in the study of muscle regenerative diseases, including muscular dystrophy. -
Prostaglandin Receptor Inhibitor
RS-61756-007 is a selective thromboxane receptor (TP) agonist that exhibits high affinity and activity specifically at the TP receptor. In vitro studies demonstrate that RS-61756-007 also shows agonistic effects at FP receptors, while remaining inactive against other receptor subtypes. The biological effects of RS-61756-007 can be effectively inhibited by the TP antagonist SQ 29,548. This compound is valuable for research aimed at understanding thromboxane signaling and its implications in various physiological and pathological processes. -
Thromboxane Synthetase Inhibitor
Y-20811 sodium is a selective thromboxane synthetase inhibitor that exhibits potent and irreversible inhibition of thromboxane A2 synthesis. This compound is primarily utilized in cardiovascular research, particularly in studying thrombosis and its associated pathophysiological mechanisms. Its oral bioactivity makes it a valuable tool for investigating therapeutic interventions in thromboxane-related vascular disorders. -
Thromboxane Inhibitor
BM567 is a potent thromboxane A2 receptor (TXR) antagonist and thromboxane A2 synthase (TXS) inhibitor, with IC50 values of 1.1 nM and 12 nM, respectively. This sulfonylurea compound demonstrates significant antithrombogenic activity, making it a valuable tool for studying thromboxane signaling pathways in various biological contexts. Its application extends to research on cardiovascular diseases and the role of thromboxane in platelet aggregation and vasoconstriction. -
Thromboxane A2 Receptor Inhibitor
Samixogrel is a potent thromboxane A2 receptor inhibitor that modulates thromboxane synthesis. Its mechanism of action involves blocking the thromboxane A2 signaling pathway, which is crucial for platelet aggregation and vascular constriction. This compound is primarily utilized in research related to cardiovascular disease and thrombotic disorders, providing valuable insights into the role of thromboxane A2 in pathophysiological processes. -
Prostaglandin Receptor Inhibitor
15(S)-Latanoprost is a potent agonist of prostaglandin receptors, exhibiting reduced activity compared to its parent compound, latanoprost. In a binding assay utilizing cat iris sphincter muscle, 15(S)-latanoprost demonstrated an IC50 value of 24 nM. Furthermore, administration of 3 μg of 15(S)-latanoprost resulted in a measurable decrease in intraocular pressure (IOP) by 1 mmHg in normotensive cynomolgus monkeys. This compound is valuable for research into ocular conditions and the modulation of intraocular pressure. -
Thromboxane Synthetase Inhibitor
Dazmegrel is a thromboxane synthetase inhibitor that effectively reduces the synthesis of Thromboxane A2 (TXA2), demonstrating antiplatelet and vasodilator properties. This compound is valuable in research focused on thrombosis and the modulation of platelet aggregation, making it a useful tool for studying cardiovascular diseases and related therapeutic interventions. -
TXA2 Synthase/TP-Receptor Inhibitor
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP receptor). It exhibits significant biological activity in preventing thrombus formation by modulating arachidonic acid metabolism. ICI D1542 is utilized in research applications focused on cardiovascular diseases and thrombotic disorders, providing insights into the role of TXA2 in vascular biology. -
Prostaglandin Receptor Inhibitor
Ciproquazone is a prostaglandin receptor inhibitor that effectively reduces prostaglandin biosynthesis. It exhibits a relative inhibitory potency that falls between indomethacin and aspirin, making it a relevant tool for research in inflammatory processes. Its reversible mode of action allows for precise modulation in experimental settings, facilitating studies in pain management and related pharmacological applications. -
TX Synthetase Inhibitor
LG 82-4-01 is a selective thromboxane (TX) synthetase inhibitor, exhibiting an IC50 of 1.3 μM. This compound effectively inhibits the synthesis of thromboxanes, which are implicated in various cardiovascular and inflammatory processes. LG 82-4-01 is useful in studying TX-mediated pathways and assessing potential therapeutic interventions in related diseases. -
Prostaglandin E2 Inhibitor
Camonagrel is a potent inhibitor of Prostaglandin E2, targeting thromboxane synthase to decrease the biosynthesis of thromboxane. This compound exhibits significant anti-inflammatory properties and is useful in research applications focused on cardiovascular disease and inflammation pathways. Its inhibition of Prostaglandin E2 makes it a valuable reagent for studies investigating platelet aggregation and vascular function. -
FP Receptor Inhibitor
CAY10509 is a potent inhibitor of the FP receptor, characterized by an IC50 value of 30 nM. As a PGF2α analog, it serves as a valuable tool for investigating physiological regulatory mechanisms associated with prostaglandin signaling. This reagent is suitable for applications in pharmacological studies and the exploration of inflammatory processes in various biological systems. -
Prostaglandin Receptor Inhibitor
MF-592 is a potent inhibitor of the prostaglandin E2 (PGE2) receptor, demonstrating an IC50 value of 3 nM. This compound exhibits favorable pharmacokinetic properties in both rat and dog models, making it a valuable tool for research in inflammation and pain modulation. Its selective inhibition of PGE2 signaling pathways supports studies aimed at understanding various biological processes and developing therapeutic strategies for related diseases. -
P450 ω-Hydroxylase Inhibitor
12(S)-Hydroxy-16-heptadecynoic acid is a mechanism-based inhibitor of cytochrome P450 ω-hydroxylase, effectively targeting this enzyme to modulate its activity. With a Ki value of 1.8 μM, it demonstrates significant inhibitory potency against prostaglandin ω-hydroxylase. This compound is valuable for research applications involving metabolic studies and the modulation of lipid biosynthesis pathways. -
PGHS-2 Inhibitor
12(S)-HPEPE is a potent inhibitor of prostaglandin endoperoxide synthase-2 (PGHS-2), functioning as a lipoxygenase product. This compound demonstrates significant anti-inflammatory activity by reducing interleukin 1h (IL-1h)-induced PGHS-2 expression in human lung microvascular endothelial cells. Its utility in research includes the investigation of inflammatory processes and the modulation of PGHS-2 activity, providing valuable insights into therapeutic strategies for inflammatory diseases. -
Prostaglandin Receptor Inhibitor
(±)12-HEPE is a prostaglandin receptor inhibitor produced through the non-enzymatic oxidation of eicosapentaenoic acid (EPA), comprising equal parts of the 12(S)- and 12(R)- isomers. The 12(S) isomer primarily mediates its biological effects in mammalian systems, demonstrating significant inhibition of platelet aggregation with an IC50 of 24 μM, comparable to that of 12-HETE. Additionally, (±)12-HEPE effectively inhibits U46619-induced contraction in rat aorta, exhibiting IC50 values ranging from 8.6 to 8.8 μM, making it valuable for research in cardiovascular and inflammatory responses. -
Acetylation Inhibitors
O-Acetylsalicylhydroxamic acid is an acetylation inhibitor targeting prostaglandin H2 synthase (PGHS). It effectively suppresses prostaglandin E2 (PGE2) synthesis and inhibits the cyclooxygenase activity of PGHS in vitro. The compound specifically requires the active site residue Ser-529 for its action on human PGHS-1, with the S529A mutant displaying resistance to its inactivating effects, making it a valuable tool for research in inflammation and pain pathways. -
PGT Inhibitor
T26A is a highly selective inhibitor of the prostaglandin transporter (PGT), specifically targeting PGT-mediated influx of prostaglandin E2 (PGE2). By blocking PGT activity, T26A effectively elevates extracellular PGE2 levels while reducing intracellular PGE2 metabolites and slowing the metabolism of injected PGE2 in Rattus norvegicus. This compound is valuable for research focused on understanding PGT function in adult animal models without affecting PGE2 synthesis. -
Thromboxane Synthase Inhibitor
Ro 23-3423 is a selective thromboxane synthase inhibitor with an IC50 of 0.33 μM for human platelet microsomal thromboxane synthase. This compound elevates plasma levels of prostaglandin F (PGF) and prostaglandin E2 (PGE2) in a dose-dependent manner, while reducing mean systemic arterial pressure and systemic vascular resistance. Ro 23-3423 serves as a valuable tool in the investigation of cardiovascular dynamics and the mechanisms underlying general anesthesia. -
Platelet Aggregation Inhibitor
CRL42872 free base is a potent oral platelet aggregation inhibitor that targets the mechanisms involved in platelet activation and aggregation. It effectively modulates platelet function, making it valuable for studying various cardiovascular and thrombotic disorders. Researchers can utilize CRL42872 free base to explore its potential therapeutic applications and elucidate the role of platelet aggregation in disease mechanisms. -
Prostaglandin Receptor Inhibitor
KF 13218 is a potent and selective inhibitor of thromboxane B2 (TXB2) synthase, exhibiting an IC50 value of 5.3 ± 1.3 nM. This compound effectively modulates prostaglandin receptor activity, making it valuable for research focused on inflammatory responses and cardiovascular disease pathways. Its long-lasting inhibition of TXB2 synthesis supports investigations into therapeutic strategies for conditions associated with excessive thromboxane production. -
PAR2 Inhibitor
PAR-2-IN-1 is a selective inhibitor of protease-activated receptor-2 (PAR2), targeting the PAR2 signaling pathway. This compound exhibits significant anti-inflammatory and anticancer properties, making it a valuable tool in research. Its capabilities provide insights into the role of PAR2 in various biological processes and diseases, facilitating the investigation of therapeutic interventions in inflammation and cancer. -
TRAP/ACP5 Inhibitor
CBK289001 is an inhibitor of tartrate-resistant acid phosphatase (TRAP/ACP5). It effectively inhibits TRAP 5bMV, TRAP 5bOX, and TRAP 5aOX with IC50 values of 125 µM, 4.21 µM, and 14.2 µM, respectively. This compound is useful for studying the role of TRAP in various biological processes and may aid in the development of therapeutic strategies targeting TRAP-related pathways. -
Mast Cell Tryptase Inhibitor
APC 366 TFA is an irreversible inhibitor of mast cell tryptase, a key enzyme involved in allergic responses. This reagent is instrumental in research focused on allergic diseases and related inflammatory processes. Its ability to effectively inhibit tryptase makes it a valuable tool for studying the mechanisms underlying mast cell activation and associated pathologies. -
PAR4 Inhibitor
PAR4 Antagonist 4 is a selective inhibitor of protease-activated receptor 4 (PAR4), demonstrating potent antiplatelet activity with an IC50 of 14.2 nM. This compound exhibits enhanced metabolic stability in human liver microsomes, with a half-life (T1/2) of 42.5 minutes. PAR4 Antagonist 4 is suitable for research applications focused on hemostasis, cardiovascular disorders, and the modulation of platelet activation pathways. -
PAR4 Inhibitor
PAR4 antagonist 3 is a selective inhibitor of protease-activated receptor 4 (PAR4). This compound demonstrates significant antiplatelet activity, with an IC50 value of 26.1 nM, making it a valuable tool for studies related to thrombosis and platelet function. Additionally, PAR4 antagonist 3 shows improved metabolic stability in human liver microsomes, with a half-life of 97.6 minutes, enhancing its potential for in vivo applications.
